Lotte Holdings Targets the Booming Obesity Market with Strategic Biotech Investment
Tokyo, Thursday, 19 March 2026.
Signaling a major shift, Japanese conglomerate Lotte has invested in Alveus Therapeutics to target the global obesity drug market, a sector projected to exceed $100 billion by 2030.
A Strategic Pivot into Life Sciences
On March 19, 2026, Tokyo-based LOTTE Holdings Co., Ltd. announced that its healthcare and biopharmaceutical corporate venture capital (CVC) arm finalized an investment in Alveus Therapeutics [1][2]. This transaction marks the seventh investment made by the conglomerate’s dedicated life sciences fund [2]. While LOTTE is traditionally recognized for its origins in the food and chewing gum industry dating back to its establishment in 1948—giving the group a 78-year operational history—it now manages operations across approximately 30 countries and regions [1][2]. This latest capital injection underscores a broader corporate strategy to create new business avenues by integrating opportunities from Japan and South Korea [1][2].
Pioneering Next-Generation Metabolic Treatments
Founded in 2023, Alveus Therapeutics is a clinical-stage biotechnology firm headquartered in Philadelphia, Pennsylvania, with research and development operations based in Copenhagen, Denmark [1][2]. The company is engineering a portfolio of long-acting biologic drugs built upon established biological knowledge of incretin and amylin hormones [2]. The global market for these types of obesity and metabolic disease therapies is on a steep upward trajectory, projected to surpass the $100 billion mark by 2030 and continue its expansion through 2035 [1][2] [alert! ‘Market projections for 2030 and 2035 are forward-looking estimates and subject to macroeconomic and industry fluctuations’].
Broadening the Therapeutic Pipeline
Beyond its primary asset, Alveus is actively advancing a broader pipeline targeting body composition improvements and enhanced patient adherence through both injectable and oral delivery methods [2]. A key component of this expansion is ALV-200, a highly selective amylin receptor agonist [1][2]. This next-generation therapeutic candidate is currently advancing through Investigational New Drug (IND) enabling studies, the critical regulatory step required before human clinical trials can commence [1][2].